ALRN
Income statement / Annual
Last year (2024), Aileron Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Aileron Therapeutics, Inc.'s net income was -$62.88 M.
See Aileron Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$119.00 K
|
$169.00 K
|
$121.00 K
|
$163.00 K
|
$155.00 K
|
$218.00 K
|
$95.00 K
|
$232.00 K
|
$325.00 K
|
| Gross Profit |
$0.00
|
-$119.00 K
|
-$169.00 K
|
-$121.00 K
|
-$163.00 K
|
-$155.00 K
|
-$218.00 K
|
-$95.00 K
|
-$232.00 K
|
-$325.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$14.25 M
|
$3.99 M
|
$17.97 M
|
$17.01 M
|
$11.17 M
|
$17.66 M
|
$18.45 M
|
$14.24 M
|
$10.28 M
|
$7.83 M
|
| General & Administrative Expenses |
$13.86 M
|
$11.36 M
|
$9.68 M
|
$9.60 M
|
$9.33 M
|
$12.29 M
|
$13.45 M
|
$8.77 M
|
$7.89 M
|
$5.06 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.86 M
|
$11.36 M
|
$9.68 M
|
$9.60 M
|
$9.33 M
|
$12.29 M
|
$13.45 M
|
$8.77 M
|
$7.89 M
|
$5.06 M
|
| Other Expenses |
$37.00 M
|
$928.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$18.17 M
|
$0.00
|
| Operating Expenses |
$65.11 M
|
$16.28 M
|
$27.65 M
|
$26.61 M
|
$20.50 M
|
$29.96 M
|
$31.90 M
|
$23.01 M
|
$18.17 M
|
$12.89 M
|
| Cost And Expenses |
$0.00
|
$16.28 M
|
$27.65 M
|
$26.61 M
|
$20.50 M
|
$29.96 M
|
$31.90 M
|
$23.01 M
|
$18.17 M
|
$12.89 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$587.00 K
|
$355.00 K
|
$404.00 K
|
$46.00 K
|
$13.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$119.00 K
|
$169.00 K
|
$121.00 K
|
$163.00 K
|
$155.00 K
|
$218.00 K
|
$95.00 K
|
$232.00 K
|
$325.00 K
|
| EBITDA |
-$65.11 M |
-$15.61 M |
-$27.48 M |
-$26.48 M |
-$20.33 M |
-$29.80 M |
-$31.33 M |
-$23.01 M |
-$17.94 M |
-$12.57 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.23 M
|
$544.00 K
|
$318.00 K
|
$441.00 K
|
-$661.00 K
|
$587.00 K
|
$355.00 K
|
$404.00 K
|
$46.00 K
|
$13.00 K
|
| Income Before Tax |
-$62.88 M
|
-$15.73 M
|
-$27.33 M
|
-$26.21 M
|
-$21.16 M
|
-$29.37 M
|
-$31.55 M
|
-$22.60 M
|
-$18.12 M
|
-$12.88 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$441.00 K
|
$0.00
|
$0.00
|
$0.00
|
$34.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$62.88 M
|
-$15.73 M
|
-$27.01 M
|
-$25.76 M
|
-$21.82 M
|
-$28.78 M
|
-$31.55 M
|
-$22.60 M
|
-$18.12 M
|
-$12.88 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.51 |
-3.42 |
-5.95 |
-5.8 |
-12.52 |
-23.46 |
-42.81 |
-30.7 |
-33.21 |
-23.6 |
| EPS Diluted |
-3.51 |
-3.42 |
-5.95 |
-5.8 |
-12.52 |
-23.46 |
-42.81 |
-30.7 |
-33.21 |
-23.6 |
| Weighted Average Shares Out |
$17.94 M
|
$4.60 M
|
$4.54 M
|
$4.44 M
|
$1.74 M
|
$1.23 M
|
$736.91 K
|
$736.40 K
|
$545.72 K
|
$545.72 K
|
| Weighted Average Shares Out Diluted |
$17.94 M
|
$4.60 M
|
$4.54 M
|
$4.44 M
|
$1.74 M
|
$1.23 M
|
$736.91 K
|
$736.40 K
|
$545.72 K
|
$545.72 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
